재발 또는 내화성 T 세포 비호 지킨 림프종을 가진 참가자에서 KK2223에 대한 최초의 인간 연구
1 상, 다기관, 오픈 라벨, 비 랜덤 화, 복용량 에스컬레이션 및 재발 성 T- 세포 비 호 지킨 림프종을 가진 참가자의 KK2223의 백필 연구
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Kyowa Kirin, Inc.
- 전화번호: +1-609-919-1100
- 이메일: KKD.Clinical.82@kyowakirin.com
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- 아직 모집하지 않음
- City of Hope
-
수석 연구원:
- Christina Poh
-
연락하다:
- Christina Poh
- 전화번호: 916-734-7131
- 이메일: cpoh@coh.org
-
Orange, California, 미국, 92868
- 아직 모집하지 않음
- University of California, Irvine Medical Center - Hematology/Oncology
-
연락하다:
- Lauren Pinter Brown
- 전화번호: 7144568200
- 이메일: lpinterb@uci.edu
-
수석 연구원:
- Lauren Pinter Brown
-
Stanford, California, 미국, 94305
- 모병
- Stanford University School of Medicine
-
수석 연구원:
- Youn Kim
-
연락하다:
- Youn Kim
- 전화번호: 650-723-7893
- 이메일: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, 미국, 33612
- 아직 모집하지 않음
- Moffit Cancer Center
-
연락하다:
- Yumeng Zhang
- 전화번호: 844-304-8636
- 이메일: yumeng.zhang@moffitt.org
-
수석 연구원:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 아직 모집하지 않음
- Emory University Medical Center
-
수석 연구원:
- Pamela Allen
-
연락하다:
- Pamela Allen
- 전화번호: 404-778-2407
- 이메일: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 아직 모집하지 않음
- University of Iowa Health
-
수석 연구원:
- Eric Mou
-
연락하다:
- Eric Mou
- 전화번호: 800-777-8442
- 이메일: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 아직 모집하지 않음
- Beth Israel Deaconess Medical Center - Research
-
연락하다:
- Salvia Jain
- 전화번호: 617-726-2000
- 이메일: salvia.jain@mgh.harvard.edu
-
수석 연구원:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine - Oncology Hospital - Public
-
수석 연구원:
- Neha Mehta Shah
-
연락하다:
- Neha Mehta Shah
- 전화번호: 314.273-8566
- 이메일: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601-2105
- 아직 모집하지 않음
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
수석 연구원:
- Tatyana Feldman
-
연락하다:
- Tatyana Feldman
- 전화번호: 551-996-5900
- 이메일: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, 미국, 10021-6007
- 모병
- Memorial Sloan Kettering Cancer Center
-
수석 연구원:
- Jasmine Zain
-
연락하다:
- Jasmine Zain
- 전화번호: 212-639-3045
- 이메일: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- 아직 모집하지 않음
- University Hospitals Cleveland Medical Center
-
연락하다:
- Kevin Cooper
- 전화번호: 216-844-8200
- 이메일: kevin.cooper@uhhospitals.org
-
수석 연구원:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 아직 모집하지 않음
- Oregon Health & Science University
-
연락하다:
- Craig Okada
- 전화번호: 503-494-8397
- 이메일: okadac@ohsu.edu
-
수석 연구원:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 아직 모집하지 않음
- University of Pennsylvania - Abramson Cancer Center
-
수석 연구원:
- Stefan Barta
-
연락하다:
- Stefan Barta
- 전화번호: 215-728-2674
- 이메일: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- The University of Texas - MD Anderson Cancer Center
-
수석 연구원:
- Ranjit Nair
-
연락하다:
- Ranjit Nair
- 전화번호: 171-379-2860
- 이메일: rnair@mdanderson.org
-
-
-
-
-
Madrid, 스페인, 28027
- 아직 모집하지 않음
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
연락하다:
- Miguel Canales Albendea
- 전화번호: 34917277116
- 이메일: macanales@unav.es
-
수석 연구원:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 8036
- 아직 모집하지 않음
- Hospital Clinic De Barcelona - Hematología
-
수석 연구원:
- Pablo Mozas
-
연락하다:
- Pablo Mozas
- 전화번호: 34 93 227 22 71
- 이메일: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, 스페인, 8907
- 아직 모집하지 않음
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
수석 연구원:
- Eva Domingo Domenech
-
연락하다:
- Eva Domingo Domenech
- 전화번호: 34932607822
- 이메일: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, 스페인, 31008
- 아직 모집하지 않음
- Clinica Universidad de Navarra - Hematología
-
연락하다:
- Miguel Canales Albendea
- 전화번호: 34917277116
- 이메일: macanales@unav.es
-
수석 연구원:
- Miguel Canales Albendea
-
-
-
-
-
Bergamo, 이탈리아, 24127
- 아직 모집하지 않음
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
수석 연구원:
- Giuseppe Gritti
-
연락하다:
- Giuseppe Gritti
- 전화번호: 39035269492
- 이메일: giuseppe_gritti@yahoo.it
-
Bologna, 이탈리아, 40138
- 아직 모집하지 않음
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
연락하다:
- Luigi Zinzani Pier
- 전화번호: 390516363680
- 이메일: pierluigi.zinzani@unibo.it
-
수석 연구원:
- Luigi Zinzani Pier
-
Torino, 이탈리아, 10126
- 아직 모집하지 않음
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
연락하다:
- Federica Cavallo
- 전화번호: 390116334264
- 이메일: f.cavallo@unito.it
-
수석 연구원:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, 이탈리아, 10060
- 아직 모집하지 않음
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
수석 연구원:
- Umberto Vitolo
-
연락하다:
- Umberto Vitolo
- 전화번호: 390116335934
- 이메일: umberto.vitolo@ircc.it
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
실험적: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Blood Drug Concentration
기간: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
기간: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
기간: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
기간: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
기간: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
기간: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
기간: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
기간: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2223-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .